Published in Gene Therapy Weekly, November 4th, 1996
ATIII is a plasma protein that helps prevent harmful blood clotting in many serious medical conditions. The company also announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for a Phase II trial in the United States later in 1996. The Phase II trial is aimed at a reduction in bleeding and in the amount of donor blood needed by patients undergoing coronary artery...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.